Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Quercus macrocarpa pollen is an allergenic extract derived from the pollen of the Burr Oak tree. It is primarily utilized as a diagnostic tool in clinical allergy testing, such as skin prick tests or intradermal tests, to identify individuals with IgE-mediated hypersensitivity to oak pollen. As a biologic allergenic extract, it contains specific proteins that, when introduced to a sensitized individual, cross-link allergen-specific Immunoglobulin E (IgE) on the surface of mast cells and basophils. This interaction triggers the release of inflammatory mediators like histamine, resulting in a measurable wheal-and-flare reaction. Beyond its diagnostic use, similar extracts are also employed in allergen immunotherapy (desensitization) to treat allergic rhinitis, allergic conjunctivitis, and asthma by inducing immunological tolerance over time.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on quercus macrocarpa pollen.